Letter to the Editor in response to "N Folschweiller, V Berlaimont, SR Skinner, CM Wheeler, N Karkada, F Struyf, M Ryser. Letter to the Editor in response to O.M. Bautista, A. Luxembourg. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. Contemp. Clin. Trials (2016), doi: 10.1016/j.cct.2016.12.022".
Merck & Co., Inc., Kenilworth, NJ, USA.
Oliver M
OM
Bautista
Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: alain.luxembourg@merck.com.
Alain
A
Luxembourg
D005260:Female; D006801:Humans; D053918:Papillomavirus Vaccines; D002583:Uterine Cervical Neoplasms; D002578:Uterine Cervical Dysplasia
D053918:Papillomavirus Vaccines